## **Securities**



Out think. Out perform.

### Slow burner

JAKS's 3Q15 results were below our expectations, partly on weakerthan-expected construction profit as a result of licensing delays. However, the issue has been resolved, and progress billings should pick up in 4Q15. Once it receives a legal opinion from the Vietnam Ministry of Justice expected in Nov-15, JAKS should be close to financial closure on the Vietnam power plant project. BUY.

#### 9M15 results below expectations

JAKS's 9M15 results were below our expectations. 9M15 core net profit of RM12.2m (+73.4% yoy) accounted for just 54% of our full-year forecast due to lower-than-expected property unbilled sales recognition and construction profit. No dividends were declared.

#### Delays in licensing pull down construction division

While 3Q15 revenue grew 21.7% yoy, JAKS's results were a miss because we had expected stronger revenue from its construction and property segments. 3Q15 construction revenue fell by 10.4% qoq due to delays in obtaining certain licenses from government authorities that were subsequently resolved in 4Q15. The property division (+9.3% yoy) recognised more unbilled sales in 3Q15, but was below our expectations due to prevailing soft market conditions. Property unbilled sales stood at RM364m in 3Q15 (2Q15: RM386m). On stable margins, lower finance costs and tax, JAKS's 3Q15 net profit doubled yoy.

#### **Developments in 4Q15**

We gather from management that JAKS is on track to receive an issuance of legal opinion in Nov-15 by the Vietnam Ministry of Justice for the power plant project. With this in mind, we still expect the project to begin construction in 1Q16 and therefore make no changes to our FY16-17E EPS. We however lower our FY15E EPS by 15.9% to reflect the weaker-than-expected 9M15 results.

#### Maintain BUY rating and TP of RM1.60

We maintain our BUY call and make no change to our 12-month target price of RM1.60, based on a 20% discount to our RNAV (realisable net asset value) valuation of RM2.00, as our FY16-17E EPS remain unchanged. We believe JAKS is still on track to unlock value in its Vietnam project. Additional water-related infrastructure project wins and positive earnings surprises from the construction of non-technical work on the Vietnam project would be key rerating catalysts for JAKS, in our view.

Earnings & Valuation Summary

Earnings & Valuation Summary						
FYE 31 Dec	2013	2014	2015E	2016E	2017E	
Revenue (RMm)	586.4	491.1	483.8	924.7	939.7	
EBITDA (RMm)	42.7	73.8	67.2	189.0	191.8	
Pretax profit (RMm)	19.8	53.9	47.2	169.3	172.3	
Net profit (RMm)	7.5	14.0	18.9	67.7	68.9	
EPS (sen)	1.7	3.2	4.3	15.4	15.7	
PER (x)	67.8	36.4	26.9	7.5	7.4	
Core net profit (RMm)	7.5	14.0	18.9	67.7	68.9	
Core EPS (sen)	1.7	3.2	4.3	15.4	15.7	
Core EPS growth (%)	172.8	86.1	35.3	258.3	1.8	
Core PER (x)	67.8	36.4	26.9	7.5	7.4	
Net DPS (sen)	0.0	0.0	0.0	0.0	0.0	
Dividend Yield (%)	0.0	0.0	0.0	0.0	0.0	
EV/EBITDA (x)	24.5	16.4	18.1	6.4	6.3	
Chg in EPS (%)			(15.9)	-	-	
Affin/Consensus (x)			0.9	0.8	0.7	

**Results Note** 

## **JAKS Resources**

JAK MK Sector: Utilities

RM1.16 @ 17 Nov 2015

## **BUY** (maintain)

Upside 38%

# Price Target: RM1.60 Previous Target: RM1.60



#### **Price Performance**

	1M	3M	12M
Absolute	+0.9%	+50.6%	+112%
Rel to KLCI	+4.0%	+42.2%	+130%

#### **Stock Data**

Issued shares (m)	438.4
Mkt cap (RMm)/(US\$m)	508.5/116.0
Avg daily vol - 6mth (m)	5.7
52-wk range (RM)	0.38-1.24
Est free float	75%
BV per share (RM)	1.06
P/BV (x)	1.09
Net cash/(debt) (RMm) (3Q15)	(501.5)
ROE (2015E)	12.3%
Derivatives	Nil
Shariah Compliant	No

#### **Kev Shareholders**

Ang Lam Poah	7.4%
Original Invention	5.0%
Dimensional Fund	4.1%
Source: Affin Hwana, Bloombera	

Lim Tee Yang, CFA (603) 2145 9616 teeyang.lim@affinhwang.com

## **Securities**



Out think. Out perform.

#### **Risks**

The key risk to our view lies in a potential delay or an inability to secure financial closure for the Vietnam project, as it is a significant component of our valuation for JAKS. Other risks include delays in monetising the shopping mall and slower-than-expected property sales.

Fig 1: Results comparison

FYE 31 Dec (RMm)	3Q15	QoQ	YoY	9M15	YoY	Comments
		% chg	% chg		% chg	
Revenue	114.2	29.3	21.7	314.2	4.1	Better yoy in 9M15 mainly due to higher construction revenue (+70.5% yoy).
Op costs	(98.8)	31.8	21.7	(272.9)	6.2	, , , , , , , , , , , , , , , , , , , ,
EBITDA	15.3	15.4	21.9	41.4	(7.5)	
EBITDA margin (%)	13.4	-1.6ppt	+0.0ppt	13.2	-1.7ppt	
Depn and amort	(8.0)	(14.0)	(31.1)	(2.7)	(11.5)	
EBIT	14.5	17.6	27.4	38.7	(7.2)	
Int expense	(4.3)	11.2	56.9	(11.8)	12.3	
Pretax profit	10.2	20.6	17.9	26.8	(13.8)	
Tax	(2.5)	(21.0)	(18.3)	(8.3)	(24.6)	
Tax rate (%)	24.6	-13.0ppt	-10.9ppt	31.0	-4.4ppt	
MI	(1.8)	(12.5)	(36.9)	(6.3)	(51.8)	
Net profit	5.9	81.4	112.7	12.2	73.4	Lower yoy partly due to higher finance costs
EPS (sen)	1.4	82.4	114.3	2.8	73.3	
Core net profit	5.9	81.4	112.7	12.2	73.4	Below Affin Hwang expectations.

Fig 2: JAKS RNAV Valuation

	Equity Value	
JAKS RNAV Segmental	(RMm)	Comments
Property		
- Pacific Star	33.3	51% stake in RM1.2bn GDV due for completion by 2016; c.RM400m of unbilled sales plus c.RM100m of unsold units.
- USJ 1	107.1	100% stake in GDV of RM2.0bn (5-year development) assuming 2016 launch.
Construction	490.0	PER at 10x based on 2016E net profit of RM49m, which includes non-technical work from Vietnam project.
Mall	234.6	51% stake of 460k sq ft NLA @ RM1,000 psf.
Gross debt	(601.6)	
Cash balance	41.6	
Total RNAV (without Vietnam project)	305.0	
RNAV/per share (RM)	0.70	
Vietnam IPP	571.7	With financial closure @ 30% stake (WACC: 10.2%, IRR: 14%).
Total RNAV (with Vietnam project)	876.7	
RNAV/per share (RM)	2.00	
Discount to total RNAV (with Vietnam project)	20.0%	
Target price (RM)	1.60	
No of shares (mil)	438.4	

Source: Affin Hwang estimates

#### Securities



Out think. Out perform.

#### Disclaimer

#### **Equity Rating Structure and Definitions**

BUY Total return is expected to exceed +10% over a 12-month period

**HOLD** Total return is expected to be between -5% and +10% over a 12-month period

**SELL** Total return is expected to be below -5% over a 12-month period

NOT RATED Affin Hwang Investment Bank Berhad does not provide research coverage or rating for this company. Report is intended as information only and not as a

recommendation

The total expected return is defined as the percentage upside/downside to our target price plus the net dividend yield over the next 12 months.

OVERWEIGHT Industry, as defined by the analyst's coverage universe, is expected to outperform the KLCI benchmark over the next 12 months

NEUTRAL Industry, as defined by the analyst's coverage universe, is expected to perform inline with the KLCI benchmark over the next 12 months

UNDERWEIGHT Industry, as defined by the analyst's coverage universe is expected to under-perform the KLCI benchmark over the next 12 months

This report is intended for information purposes only and has been prepared by Affin Hwang Investment Bank Berhad (14389-U) (formerly known as HwangDBS Investment Bank Berhad) ("the Company") based on sources believed to be reliable. However, such sources have not been independently verified by the Company, and as such the Company does not give any guarantee, representation or warranty (express or implied) as to the adequacy, accuracy, reliability or completeness of the information and/or opinion provided or rendered in this report. Facts, information, views and/or opinion presented in this report have not been reviewed by, may not reflect information known to, and may present a differing view expressed by other business units within the Company, including investment banking personnel. Reports issued by the Company, are prepared in accordance with the Company's policies for managing conflicts of interest arising as a result of publication and distribution of investment research reports. Under no circumstances shall the Company, its associates and/or any person related to it be liable in any manner whatsoever for any consequences (including but are not limited to any direct, indirect or consequential losses, loss of profit and damages) arising from the use of or reliance on the information and/or opinion provided or rendered in this report. Any opinions or estimates in this report are that of the Company, as of this date and subject to change without prior notice. Under no circumstances shall this report be construed as an offer to sell or a solicitation of an offer to buy any securities. The Company and/or any of its directors and/or employees may have an interest in the securities mentioned therein. The Company may also make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

Comments and recommendations stated here rely on the individual opinions of the ones providing these comments and recommendations. These opinions may not fit to your financial status, risk and return preferences and hence an independent evaluation is essential. Investors are advised to independently evaluate particular investments and strategies and to seek independent financial, legal and other advice on the information and/or opinion contained in this report before investing or participating in any of the securities or investment strategies or transactions discussed in this report.

Third-party data providers make no warranties or representations of any kind relating to the accuracy, completeness, or timeliness of the data they provide and shall not have liability for any damages of any kind relating to such data.

The Company's research, or any portion thereof may not be reprinted, sold or redistributed without the consent of the Company.

The Company, is a participant of the Capital Market Development Fund-Bursa Research Scheme, and will receive compensation for the participation.

This report is printed and published by:
Affin Hwang Investment Bank Berhad (14389-U)
(formerly known as HwangDBS Investment Bank Berhad)
A Participating Organisation of Bursa Malaysia Securities Bhd
Chulan Tower Branch,
3rd Floor, Chulan Tower,
No 3, Jalan Conlay,
50450 Kuala Lumpur.
www.affinhwang.com

Email: affin.research@affinhwang.com

Tel: + 603 2143 8668 Fax: + 603 2145 3005